Business Context and Reporting Period
This Form 8-K Current Report, dated March 12, 2023, is filed by AcelRx Pharmaceuticals, Inc. (ACRX). The filing details the entry into a Material Definitive Agreement involving the sale of assets related to its sufentanil sublingual tablet products (DSUVIA and DZUVEO) and the termination of a prior manufacturing agreement.
Key Financial Metrics and Transaction Terms
The filing outlines the financial structure of the Asset Purchase Agreement with Vertical Pharmaceuticals, LLC (a subsidiary of Alora Pharmaceuticals, LLC). Key financial terms include:
- Sales-Based Milestones: Up to $116.5 million payable to AcelRx.
- Quarterly Royalties: 15% of net sales of the Product to all customers, excluding sales to the U.S. Department of Defense (DoD).
- DoD Sales: AcelRx retains the exclusive right to market to the DoD and will receive 75% of net sales from this channel.
- License/Sale Proceeds: 20% of consideration received by the Buyer from third-party licenses or asset transfers related to the Product.
- Complementary Payment: A one-time payment of EUR 1,500,000 from Aguettant to AcelRx under an amended agreement.
The filing does not provide current revenue, profit, cash flow, or debt figures for the company.
Material Changes and Agreements
Three primary material changes were executed on March 12, 2023:
- Asset Sale: AcelRx agreed to sell assets and assume liabilities related to DSUVIA and DZUVEO to Vertical Pharmaceuticals. The transaction excludes Zalviso (15 mcg) and multi-dose systems.
- Agreement Amendments with Aguettant:
- Termination of Aguettant's sales-based milestone and minimum sales obligations for DZUVEO in Europe.
- Modification of supply terms: AcelRx will supply bulk products/tablets while Aguettant handles finished product manufacturing.
- Termination of a specific sales-milestone payment obligation by AcelRx under the PFS Agreement.
- Termination of Catalent Agreement: AcelRx terminated the Site Readiness Agreement and Commercial Supply Agreement with Catalent Pharma Solutions, LCC, effective upon the removal of equipment from Catalent's site.
Outlook, Risks, and Contingencies
Closing Conditions: The asset sale is subject to customary conditions, including the execution of amended agreements with Aguettant and the absence of a material adverse effect.
Commercialization Reversion: If the Buyer fails to commercialize, sell, and distribute the Product within six months of July 1, 2023, all rights granted to the Buyer will revert to AcelRx upon written notice.
Future Filings: Pro forma financial information regarding the disposition is expected to be filed within four business days of the Closing.
Investor Verification Checklist
- Verify the exact closing date of the Asset Purchase Agreement to confirm the start of royalty payments and milestone eligibility.
- Review the full text of the Purchase Agreement and ancillary agreements (IP, transition services, marketing) to be filed in the Q1 2023 Form 10-Q.
- Monitor the Buyer's progress on commercialization to assess the risk of rights reverting to AcelRx by January 2024.
- Confirm the receipt of the EUR 1,500,000 complementary payment from Aguettant and its impact on cash flow.
- Assess the operational impact of terminating the Catalent supply agreement and the transition of manufacturing responsibilities.